Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9-10, 2025. The Corbus session is scheduled for October 9, 2025 at 10:00AM ET and will be hosted by Biren Amin, Managing Director, Piper Sandler Healthcare Equity Research.

Piper Sandler clients can register through their representative. The participation is a presentation event and does not include new financial guidance or clinical readout details.

NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium, to be held October 9-10, 2025. Piper Sandler clients can register for the event through their representative.

Corbus Fireside Chat
October 9, 2025, 10:00AM ET
Hosted by Biren Amin, Managing Director
Pipe Sandler - Healthcare Equity Research

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

When will Corbus (CRBP) present at the Piper Sandler Virtual Oncology Symposium?

Corbus will present on October 9, 2025 at 10:00AM ET as part of the October 9-10, 2025 symposium.

Who from Corbus (CRBP) will participate in the Fireside Chat at the October 2025 symposium?

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the Fireside Chat.

How can Piper Sandler clients register for Corbus's (CRBP) presentation on October 9, 2025?

Piper Sandler clients can register for the event through their Piper Sandler representative.

Who is hosting the Corbus (CRBP) Fireside Chat at the Piper Sandler event?

The Fireside Chat will be hosted by Biren Amin, Managing Director, Piper Sandler Healthcare Equity Research.

Will Corbus (CRBP) release new clinical or financial data at the October 9, 2025 presentation?

The announcement describes a Fireside Chat presentation only and does not state any planned release of new clinical or financial data.